Home / Markets / Stock Market News / US sales momentum, margin gains to support pharma major Cipla's stock

US sales momentum, margin gains to support pharma major Cipla's stock

Led by the US market which rose by 31 per cent, the company posted a 16 per cent growth in revenues

Cipla plans acquisitions to take top spot in South Africa drug market

Premium

3 min read Last Updated : Oct 31 2023 | 11:44 PM IST

Listen to This Article

A strong performance in the July-September quarter of 2023-24 (Q2FY24), an upward revision in the margin guidance and sustained momentum in US sales has helped the stock of pharmaceutical major Cipla gain about 2 per cent over the last two trading sessions.

The brokerages have upgraded the earnings estimates for this financial year (FY24) by 6-9 per cent to factor in the improved margin guidance and sales in the US market.

Led by the US market, which rose by 31 per cent, the company posted a 16 per cent growth in revenues.

The US market has accounted for 28 per

Topics : Cipla pharmaceutical firms US markets stock market trading

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in